Retatrutide vs Tirzepatide: How They Compare

Retatrutide and tirzepatide are both once-weekly injections made by Eli Lilly, but they sit at very different points in their life cycle. Tirzepatide (sold as Mounjaro and Zepbound) is FDA approved and available by prescription right now. Retatrutide is still investigational and isn’t available anywhere. Tirzepatide acts on two hormone receptors; retatrutide acts on three. In separate trials, retatrutide has produced higher average weight loss, but the two drugs have never been tested against each other, so any comparison comes with caveats. Here’s how they line up on mechanism, results, side effects, availability, and cost.

The Quick Comparison

How They Work: Two Receptors vs Three

Both drugs copy gut hormones that influence appetite and metabolism, but they target a different number of them. Tirzepatide is a dual agonist, meaning it acts on the GLP-1 and GIP receptors. GLP-1 slows digestion and reduces appetite, while GIP fine-tunes insulin response and how the body handles fat. That two-pathway design is why tirzepatide outperformed single-receptor drugs in testing, and our explainer on tirzepatide for metabolic syndrome digs into why the dual mechanism matters.

Retatrutide keeps both of those receptors and adds a third: glucagon. On its own glucagon raises blood sugar, but paired with GLP-1 and GIP it appears to increase energy expenditure and push the body to burn stored fat. In short, tirzepatide works mainly by reducing how much you eat, and retatrutide adds a lever that may also increase how much energy you burn. That extra lever is the leading theory for retatrutide’s larger trial numbers.

Weight Loss Results: What the Trials Show

Tirzepatide’s results are well documented. In the SURMOUNT-1 trial, adults on the highest dose lost an average of about 21 percent of their body weight over 72 weeks. Tirzepatide has also been tested directly against semaglutide in SURMOUNT-5, where it came out ahead (about 20 percent versus 14 percent), so its standing among approved drugs is backed by head-to-head evidence. Our overview of tirzepatide weight loss results walks through what the data looks like in practice.

Retatrutide’s numbers are higher on paper. Its Phase 2 trial showed around 24 percent weight loss at 48 weeks, and Phase 3 topline results reported in late 2025 and 2026 reached roughly 28 percent at 68 weeks. Here’s the important caveat, though. These figures come from separate trials with different participants, doses, and durations, and some of the Phase 3 data is still topline rather than fully published. Retatrutide has never been compared directly to tirzepatide. So while the trend points toward retatrutide producing more weight loss, “higher in its own trials” is not the same as “proven better in a fair fight.”

Consider this scenario: someone reads that retatrutide hit 28 percent and tirzepatide hit 21 percent and assumes the gap is settled. In reality, trial-to-trial comparisons can be skewed by who enrolled and how long they were followed. The honest read is that retatrutide looks very promising, and tirzepatide is a proven, available option today.

Side Effects: Mostly Similar, With Two Differences

The day-to-day side effects overlap a lot. Both drugs most commonly cause gastrointestinal symptoms, nausea, vomiting, diarrhea, and constipation, which are dose-dependent and tend to ease after each dose increase. Where they diverge is the glucagon component. Retatrutide produced a modest dose-dependent rise in heart rate of roughly 5 to 10 beats per minute in trials, a bit higher than tirzepatide’s, along with reports of altered skin sensation at higher doses. Tirzepatide’s safety profile also has years of real-world use behind it now, while retatrutide’s is still being mapped through ongoing trials. Neither is a small commitment, which is why both belong under medical supervision.

Availability and Cost: The Real Dividing Line

This is where the comparison actually lands for anyone deciding today. Tirzepatide is FDA approved, available by prescription, and has established pricing and insurance pathways. Retatrutide is not approved, has no list price, and cannot be obtained through any legal pharmacy. The “research-use-only” retatrutide sold online skips the quality, sterility, and dosing oversight of prescription medication, so it isn’t a safe or legal substitute. For practical purposes, retatrutide is a future option, not a current one.

Other Conditions Being Studied

Both drugs are being explored beyond weight loss. Tirzepatide is already FDA approved for chronic weight management and, as of late 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity, and it’s being studied in heart failure. Retatrutide’s Phase 3 program is broader still, covering obesity, type 2 diabetes, sleep apnea, liver disease, knee osteoarthritis, and cardiovascular outcomes. The difference, again, is that tirzepatide’s expanded uses are approved and available, while retatrutide’s are research in progress.

Which Is the Better Choice Right Now?

If retatrutide eventually reaches the market with results like its trial data, it could become a major option, especially for people who need more than current medications deliver. But you can’t choose it today. The realistic decision is among the approved drugs, and tirzepatide is one of the most effective of those, with proven results and a clear track record. If you’re weighing approved options, our guide on how to choose between Ozempic and Mounjaro is a good starting point, and the tirzepatide results timeline shows what progress tends to look like week by week.

The best way to find the right fit for your health history and goals is a quick assessment with a provider. You can compare your options with a provider to see what makes sense for you now, and keep retatrutide on your radar as its Phase 3 results continue to come in.

This article is for educational purposes and is not medical advice. Retatrutide is an investigational medication that is not FDA approved and is not available by prescription. Consult a licensed healthcare provider before starting or changing any treatment. Individual results vary.